BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Argus Health
Daiichi Sankyo
McKinsey
Mallinckrodt
Merck
McKesson
Deloitte
Fish and Richardson

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,435,567

« Back to Dashboard

Summary for Patent: 8,435,567
Title:Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Abstract: The invention provides microparticles for use in a pharmaceutical composition for Pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Harris; Haggis (Bristol, GB), Morton; David Alexander Vodden (Bath, GB), Bannister; Robin (Essex, GB)
Assignee: Vectura Limited (Chippenham, GB)
Application Number:13/269,025
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,435,567

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,435,567

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0029261.5Nov 30, 2000
United Kingdom0030946.8Dec 19, 2000
United Kingdom0124010.0Oct 5, 2001

Non-Orange Book US Patents Family Members for Patent 8,435,567

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,541,022 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,182,791 Formulations for use in inhaler devices ➤ Subscribe
9,585,839 Particles for use in a pharmaceutical composition ➤ Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets ➤ Subscribe
8,029,768 Treatment of respiratory diseases ➤ Subscribe
8,932,635 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Subscribe
8,871,274 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,303,991 Method of making particles for use in a pharmaceutical composition ➤ Subscribe
8,580,306 Particles for use in a pharmaceutical composition ➤ Subscribe
8,956,661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,435,567

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 330585 ➤ Subscribe
Austria 339195 ➤ Subscribe
Austria 348603 ➤ Subscribe
Austria 364381 ➤ Subscribe
Austria 377416 ➤ Subscribe
Austria 378039 ➤ Subscribe
Austria 382335 ➤ Subscribe
Austria 446085 ➤ Subscribe
Austria 513542 ➤ Subscribe
Austria 517607 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Moodys
Teva
Medtronic
Accenture
Daiichi Sankyo
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot